JPMorgan lowered the firm’s price target on Nuvalent (NUVL) to $145 from $147 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology group.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- 3 ‘Strong Buy’ Stocks to Buy Today, 12/18/2025, According to Top Analysts
- Nuvalent’s Royalty Interest Acquired by Royalty Pharma
- Royalty Pharma acquires royalty interest in Nuvalent’s neladalkib, zidesamtinib
- Ron Squarer Joins Nuvalent Board as Independent Director
- Nuvalent initiated with a Buy at Truist